A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome

Published on Sep 27, 2005in Gut19.819
· DOI :10.1136/GUT.2005.077503
Jan Tack126
Estimated H-index: 126
(Katholieke Universiteit Leuven),
Dorine Broekaert8
Estimated H-index: 8
+ 3 AuthorsJozef Janssens45
Estimated H-index: 45
Sources
Abstract
Introduction: Selective serotonin reuptake inhibitors (SSRIs) are frequently used in the treatment of irritable bowel syndrome (IBS) although evidence of their efficacy is scarce. Aim: Twenty three non-depressed IBS patients were recruited from a tertiary care centre and included in a crossover trial comparing six weeks of treatment with the SSRI citalopram (20 mg for three weeks, 40 mg for three weeks) with placebo. IBS symptom severity was the primary outcome measure, and depression and anxiety scores were also measured. The effect of acute administration of citalopram on colonic sensitivity and on colonic response to feeding was investigated as a putative predictor of symptomatic response to the drug. Results: After three and six weeks of treatment, citalopram significantly improved abdominal pain, bloating, impact of symptoms on daily life, and overall well being compared with placebo. There was only a modest effect on stool pattern. Changes in depression or anxiety scores were not related to symptom improvement. The effect of acute administration of citalopram during a colonic barostat study did not predict clinical outcome. Analysis of the first treatment period as a double blind parallel arm study confirmed the benefit of citalopram over placebo. Conclusions: The SSRI citalopram significantly improves IBS symptoms, including abdominal pain, compared with placebo. The therapeutic effect is independent of effects on anxiety, depression, and colonic sensorimotor function.
Figures & Tables
Download
📖 Papers frequently viewed together
94 Citations
152 Citations
179 Citations
References19
Newest
#1Jan Tack (Katholieke Universiteit Leuven)H-Index: 126
#2Dorine Broekaert (Katholieke Universiteit Leuven)H-Index: 8
Last. Jozef Janssens (Katholieke Universiteit Leuven)H-Index: 61
view all 5 authors...
Summary Background It is unclear whether decreased serotonin transporter function contributes to sensorimotor abnormalities in irritable bowel syndrome. Aim To study the influence of acute serotonin transporter inhibition on colonic sensorimotor function in man. Methods Ten healthy subjects (five men, aged 20–29 years) underwent a combined manometry/barostat study of the descending colon on two occasions. Stepwise distentions by 2 mmHg increments were performed until discomfort. Subsequently, pl...
63 CitationsSource
#1Victoria L. Morgan (Vandy: Vanderbilt University)H-Index: 29
#2David R. PickensH-Index: 20
Last. Howard R. MertzH-Index: 21
view all 5 authors...
Background and aims: Irritable bowel syndrome (IBS) is a disorder of intestinal hypersensitivity and altered motility, exacerbated by stress. Functional magnetic resonance imaging (fMRI) during painful rectal distension in IBS has demonstrated greater activation of the anterior cingulate cortex (ACC), an area relevant to pain and emotions. Tricyclic antidepressants are effective for IBS. The aim of this study was to determine if low dose amitriptyline reduces ACC activation during painful rectal...
225 CitationsSource
#1Akio Nakai (University of Fukui)H-Index: 16
#2Mirko Diksic (Montreal Neurological Institute and Hospital)H-Index: 58
Last. Kathryn Kersey (GSK: GlaxoSmithKline)H-Index: 19
view all 5 authors...
Serotonin (5-HT) plays an important role in the pathophysiology of irritable bowel syndrome (IBS). Using a-( 11 C)methyl-L-tryptophan-positron emission tomography (PET), it was demonstrated that brain 5-HT synthesis is increased in patients with IBS, in a gender-specific manner. The aims of the study were to evaluate the effects of alosetron on brain 5-HT syn- thesis in patients with IBS. Six male and five female non-constipation-predominant IBS patients were en- rolled. The subjects received al...
21 CitationsSource
#1J. F. Johanson (UIC: University of Illinois at Chicago)H-Index: 1
This article reviews the efficacy and toler- ability of traditional therapies for irritable bowel syn- drome (IBS) and concludes that they are limited by both poor efficacy and adverse effects. Serotonin, a neurotransmitter found mainly in the gut, appears to represent a link in IBS pathophysiological processes - altered gut motility, abnormal intestinal secretion and visceral hypersensitivity. Recently, available treat- ments for IBS have targeted serotonin receptors that are involved in motor,...
23 CitationsSource
The benefit of selective serotonin reuptake inhibitors (SSRIs) in the irritable bowel syndrome (IBS) has not been clear. In the latest randomized trial published this month in the Journal, paroxetine was superior to placebo in terms of improving well-being, but not abdominal pain or bloating. Based on the results of the most recent studies, both tricyclic antidepressants and SSRIs may improve patient satisfaction or quality-of-life without relieving most of the primary gastrointestinal symptoms....
30 CitationsSource
The irritable bowel syndrome (IBS) is a complex disorder that is associated with altered gastrointestinal motility, secretion, and sensation. Serotonin (5-HT) is an important neurotransmitter and paracrine signalling molecule in the gastrointestinal tract. 5-HT release from enterochromaffin (EC) cells initiates peristaltic, secretory, vasodilatory, vagal and nociceptive reflexes. The enteric nervous system (ENS) comprises a semiautonomous effector system that is connected to the central autonomi...
180 CitationsSource
#1Howard R. Mertz (Vandy: Vanderbilt University)H-Index: 21
Irritable bowel syndrome, characterized by disordered bowel habits associated with abdominal pain or discomfort, affects roughly one in eight adults. This review discusses therapeutic options for p...
176 CitationsSource
#1Douglas A. Drossman (UNC: University of North Carolina at Chapel Hill)H-Index: 103
#2Brenda B. Toner (U of T: University of Toronto)H-Index: 43
Last. Shrikant I. Bangdiwala (UNC: University of North Carolina at Chapel Hill)H-Index: 75
view all 21 authors...
Abstract Background & aims: Studies of antidepressants and psychological treatments in functional bowel disorders (FBD) are methodologically limited. The aim of this study was to assess the clinical efficacy and safety of cognitive-behavioral therapy (CBT) against education (EDU) and desipramine (DES) against placebo (PLA) in female patients with moderate to severe FBD (irritable bowel syndrome, functional abdominal pain, painful constipation, and unspecified FBD). We also evaluated the amenabil...
525 CitationsSource
Abstract Background & Aims: Although widely prescribed, the evidence for the use of antidepressants for the treatment of irritable bowel syndrome (IBS) is limited. In this study, we hypothesized that fluoxetine (Prozac), a selective serotonin reuptake inhibitor, has visceral analgesic properties, leading to increased sensory thresholds during rectal distention and improvement of symptoms, in particular in IBS patients with visceral hypersensitivity. Methods: Forty non-depressed IBS patients unde...
179 CitationsSource
#1Francis Creed (University of Manchester)H-Index: 92
#2Lakshmi FernandesH-Index: 7
Last. Barbara TomensonH-Index: 64
view all 9 authors...
Abstract Background & Aims: Psychotherapy and antidepressants are effective in patients with severe irritable bowel syndrome (IBS), but the cost-effectiveness of either treatment in routine practice has not been established. Methods: Patients with severe IBS were randomly allocated to receive 8 sessions of individual psychotherapy, 20 mg daily of the specific serotonin reuptake inhibitor (SSRI) antidepressant, paroxetine, or routine care by a gastroenterologist and general practitioner. Primary ...
363 CitationsSource
Cited By227
Newest
#1Benjamin MisselwitzH-Index: 32
#2Reiner WiestH-Index: 41
Source
Last. Eva Latorre (University of Zaragoza)H-Index: 12
view all 4 authors...
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder whose aetiology is still unknown. Most hypotheses point out the gut-brain axis as a key factor for IBS. The axis is composed of different anatomic and functional structures intercommunicated through neurotransmitters. However, the implications of key neurotransmitters such as norepinephrine, serotonin, glutamate, GABA or acetylcholine in IBS are poorly studied. The aim of this review is to evaluate the current evidence abou...
2 CitationsSource
#1Satish S.C. Rao (Georgia Regents University)H-Index: 79
#2Enrique Coss-Adame (Georgia Regents University)H-Index: 13
Last. Deepak Nag Ayyala (Georgia Regents University)H-Index: 3
view all 6 authors...
INTRODUCTION Rectal hypersensitivity is an important pathophysiological dysfunction in irritable bowel syndrome with predominant constipation (IBS-C), whose treatment remains challenging. In a randomized controlled trial, we compared the efficacy and safety of a novel sensori-behavioral treatment, sensory adaptation training (SAT) with escitalopram. METHODS Patients with IBS-C (Rome III) with rectal hypersensitivity received 6 biweekly sessions of SAT or escitalopram 10 mg daily for 3 months. SA...
1 CitationsSource
#1Vincenzo Oliva (UNIBO: University of Bologna)
#2Matteo Lippi (UNIBO: University of Bologna)
Last. Alessandro Serretti (UNIBO: University of Bologna)H-Index: 2
view all 9 authors...
Abstract Gastrointestinal side effects (SEs) are frequently observed in patients with major depressive disorder (MDD) while taking antidepressants and may lead to treatment discontinuation. The aim of this meta-analysis is to provide quantitative measures on short-term rates of gastrointestinal SEs in MDD patients treated with second-generation antidepressants. An electronic search of the literature was conducted by using MEDLINE, ISI Web of Science – Web of Science Core Collection, and Cochrane...
Source
#1Esther Colomier (University of Gothenburg)
#2Joost AlgeraH-Index: 1
Last. Chloé MelchiorH-Index: 11
view all 3 authors...
Irritable bowel syndrome (IBS) is one of the most common disorders of the gut-brain axis, which affects approximately 4% of the global population. The Rome IV criteria define IBS as chronic or recurrent abdominal pain associated with altered bowel habits. Patients can be categorized in 4 subtypes: IBS with predominant constipation (IBS-C), predominant diarrhea (IBS-D), mixed bowel habits (IBS-M), and unclassified (IBS-U). IBS is associated with a lower quality of life, reduced work productivity,...
1 CitationsSource
#1Brian E. Lacy (Mayo Clinic)H-Index: 54
#2David Cangemi (Mayo Clinic)H-Index: 8
Last. Maria I. Vazquez-Roque (Mayo Clinic)H-Index: 16
view all 3 authors...
Abstract Abdominal bloating and distension are 2 of the most commonly reported gastrointestinal symptoms. Abdominal bloating is characterized by symptoms of trapped gas, abdominal pressure, and fullness. Abdominal distension is defined as a measurable increase in abdominal girth. These symptoms frequently co-exist, although they can occur separately. Defined by Rome IV criteria, functional abdominal bloating and distension commonly coincide with other functional gastrointestinal disorders, such ...
13 CitationsSource
#1Eric D. Shah (Dartmouth–Hitchcock Medical Center)H-Index: 8
#2Jessica K. Salwen-Deremer (Dartmouth–Hitchcock Medical Center)H-Index: 2
Last. William D. CheyH-Index: 78
view all 6 authors...
Introduction. Irritable bowel syndrome (IBS) is the most common gastroenterology referral and one of the most common gastrointestinal complaints in primary care. We performed a cost-utility analysi...
2 CitationsSource
#1D. Hoekman (UvA: University of Amsterdam)H-Index: 2
#2Arine M. VliegerH-Index: 18
Last. Marc A. Benninga (UvA: University of Amsterdam)H-Index: 82
view all 10 authors...
Background and aims Many inflammatory bowel disease (IBD) patients in remission have persisting symptoms, compatible with irritable bowel syndrome (IBS-type symptoms). We aimed to compare the effectiveness of gut-directed hypnotherapy versus standard medical treatment (SMT) for IBS-type symptoms in IBD patients. Methods In this multicenter, randomized, controlled, open label trial, patients aged 12-65 years with IBD in clinical remission (global assessment) and biochemical remission (fecal calpr...
Source
#1Sun Jung Oh (Johns Hopkins University)H-Index: 1
#2Will Takakura (Cedars-Sinai Medical Center)H-Index: 3
Last. Ali Rezaie (Cedars-Sinai Medical Center)H-Index: 32
view all 3 authors...
Irritable bowel syndrome (IBS) is a common disorder requiring complex, multidisciplinary management. Antidepressants are commonly used and recommended in guidelines for the treatment of patients with IBS. We assessed randomized controlled trials (RCTs) on antidepressants in patients with IBS, with specific attention to study design and data quality/reporting characteristics. Following a comprehensive search, data and RCT characteristics were systematically summarized. Fragility index, representi...
3 CitationsSource
#1Bahra Radhaa Hamarashid (Fırat University)H-Index: 1
#2Semih Dalkilic (Fırat University)H-Index: 3
Last. Sevda Kirbağ (Fırat University)H-Index: 2
view all 5 authors...
Nowadays irritable bowel syndrome is one of the most common functional gastrointestinal disorders (FGIDs) with global prevalence. It’s described by a change in the habit of the bowel system. Pathophysiology of IBS is unclear, therefore; IBS becomes a specific subject for many researchers to investigate and discover some biomarkers associated with IBS. Symptoms are a confusion of abdominal pain and bloating which is demonstrated according to Rome criteria. In this mini-review, we conclude that IB...